MedinCell（MEDCL）株式概要
MedinCell S.A.は製薬会社で、フランスで様々な治療分野の長時間作用型注射剤を開発している。 詳細
MEDCL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MedinCell S.A. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | €29.52 |
| 52週高値 | €39.68 |
| 52週安値 | €15.39 |
| ベータ | 1.0 |
| 1ヶ月の変化 | 14.51% |
| 3ヶ月変化 | 27.79% |
| 1年変化 | 75.30% |
| 3年間の変化 | 380.78% |
| 5年間の変化 | 226.55% |
| IPOからの変化 | 301.63% |
最新ニュース
ナラティブの更新 • Jun 19
MEDCL: Long Acting Schizophrenia Injection Pipeline Will Drive Future Share Price Upside
Analysts have nudged their price target for MedinCell slightly higher, from €34.76 to about €35.07. This reflects updated assumptions on fair value, growth, margins, and future P/E, in line with recent upward revisions seen across other covered stocks.分析記事 • Jun 17
MedinCell (ENXTPA:MEDCL) Stock Could Be 29.1% Undervalued After UZEDY And Pipeline Progress
Recent updates around MedinCell (ENXTPA:MEDCL) focus on stronger royalty income from UZEDY, progress on its Olanzapine long acting injectable toward a late 2026 US launch, and higher R&D spending that keeps the company in a loss-making phase. See our latest analysis for MedinCell. MedinCell's share price has recently given back some gains, with a 1 day share price return of 12.06% down and a 7 day share price return of 7.23% down. This is despite the 90 day share price return being 20.43% up...ナラティブの更新 • Jun 04
MEDCL: Long Acting Schizophrenia Injection Progress Will Support Future Upside
Analysts have adjusted their fair value estimate for MedinCell slightly higher, from €34.28 to €34.76. They cite updated assumptions on discount rates, long term profit margins and future P/E levels as the basis for this revision.Recent updates
ナラティブの更新 • Jun 19
MEDCL: Long Acting Schizophrenia Injection Pipeline Will Drive Future Share Price Upside
Analysts have nudged their price target for MedinCell slightly higher, from €34.76 to about €35.07. This reflects updated assumptions on fair value, growth, margins, and future P/E, in line with recent upward revisions seen across other covered stocks.分析記事 • Jun 17
MedinCell (ENXTPA:MEDCL) Stock Could Be 29.1% Undervalued After UZEDY And Pipeline Progress
Recent updates around MedinCell (ENXTPA:MEDCL) focus on stronger royalty income from UZEDY, progress on its Olanzapine long acting injectable toward a late 2026 US launch, and higher R&D spending that keeps the company in a loss-making phase. See our latest analysis for MedinCell. MedinCell's share price has recently given back some gains, with a 1 day share price return of 12.06% down and a 7 day share price return of 7.23% down. This is despite the 90 day share price return being 20.43% up...ナラティブの更新 • Jun 04
MEDCL: Long Acting Schizophrenia Injection Progress Will Support Future Upside
Analysts have adjusted their fair value estimate for MedinCell slightly higher, from €34.28 to €34.76. They cite updated assumptions on discount rates, long term profit margins and future P/E levels as the basis for this revision.ナラティブの更新 • Apr 27
MEDCL: Long-Acting Schizophrenia Injection Progress Will Drive Future Upside
The analyst price target for MedinCell has increased slightly from €33.85 to €34.28 as analysts adjust their assumptions for revenue growth, profit margins and future P/E expectations. What's in the News MedinCell and Teva Pharmaceuticals reported that the U.S. FDA accepted the New Drug Application for TEV-'749, an investigational once monthly olanzapine extended release injectable suspension for adults with schizophrenia, using MedinCell's SteadyTeq copolymer technology (Key Developments).ナラティブの更新 • Apr 10
MEDCL: Schizophrenia Injection And 2026 Sales Outlook Will Drive Upside
Narrative Update on MedinCell The analyst price target for MedinCell remains steady at €33.85, as analysts keep their fair value view, discount rate, revenue growth outlook and profit margin assumptions essentially unchanged. What's in the News MedinCell completed a follow on equity offering of 2,370,000 ordinary shares, raising €48.2295 million at a price of €20.35 per share, via a subsequent direct listing (Key Developments).ナラティブの更新 • Mar 27
MEDCL: 2026 Revenue Ramp And Schizophrenia Launch Will Drive Upside
Analysts now set their price target for MedinCell at €33.85, slightly below the prior €34.23. This reflects updated assumptions on long term profit margins and a higher future P/E multiple in their models.ナラティブの更新 • Mar 11
MEDCL: 2026 Sales Outlook And New Schizophrenia Therapy Will Drive Upside
Analysts have trimmed their price target on MedinCell by about €1.04 to reflect an updated fair value of €34.23, as they factor in revised assumptions around revenue growth, profit margins and future P/E expectations. What's in the News MedinCell completed a follow on equity offering of ordinary shares, raising about €48.23 million by issuing 2,370,000 shares at €20.35 per share, via a subsequent direct listing (Key Developments).ナラティブの更新 • Feb 25
MEDCL: 2026 Revenue Outlook And New Schizophrenia Drug Will Support Upside
Analysts have kept their price target for MedinCell steady at €35.26, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their latest update. What's in the News Teva Pharmaceuticals and MedinCell announced that the U.S. FDA has accepted the New Drug Application for TEV-'749, an olanzapine extended-release injectable suspension for adult schizophrenia treatment, using MedinCell’s SteadyTeq copolymer technology for controlled sustained drug release (Key Developments).ナラティブの更新 • Feb 09
MEDCL: 2026 Revenue Guidance Will Support Upside As Profitability Outlook Strengthens
Analysts have trimmed their price target on MedinCell to about €35.26 from roughly €36.16, citing slightly higher discount rate assumptions, modestly softer revenue growth expectations of around 61.5% and a lower projected profit margin of about 70.3%, partly offset by a higher assumed future P/E multiple near 14.5x. What's in the News MedinCell issued revenue guidance for 2026, with expected net sales in a range of $250 million to $280 million.ナラティブの更新 • Jan 25
MEDCL: Index Inclusion Will Support Upside As Profitability Outlook Strengthens
Analysts have raised their price target on MedinCell to €36.16 from €35.10, citing updated assumptions that incorporate a higher projected profit margin along with a lower future P/E multiple in their models. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which covers liquid small-cap companies across 23 developed markets, increasing its visibility to global equity investors who track MSCI benchmarks (Key Developments).ナラティブの更新 • Jan 11
MEDCL: Index Inclusion Will Support Future Upside Potential
Analysts have raised their price target on MedinCell to €35.10. The latest update reflects adjusted expectations around revenue growth, profit margins and future P/E assumptions.ナラティブの更新 • Dec 19
MEDCL: Index Inclusion And New FDA Label Will Drive Upside Potential
Analysts have marginally raised their price target on MedinCell from €34.39 to €35.10, citing slightly stronger long term revenue growth expectations that more than offset a modestly lower projected profit margin and a reduced future P E multiple. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, increasing its visibility among global institutional and index-tracking investors from 24 November 2025 (company announcement).ナラティブの更新 • Dec 05
MEDCL: Future Index Inclusion Will Drive Visibility And Earnings Upside Potential
Analysts have modestly reduced their price target for MedinCell by approximately $0.49 per share, reflecting tempered expectations for revenue growth, partially offset by improved projected profit margins and slightly lower future valuation multiples. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, boosting its visibility among global institutional investors and index-tracking funds, effective at the opening of trading on 24 November 2025 (Client Announcement) The FDA has approved UZEDY, a once monthly, subcutaneous long acting risperidone injection using MedinCell’s SteadyTeq technology, for maintenance treatment of bipolar I disorder in adults, expanding its label beyond schizophrenia (Product Related Announcement) MedinCell plans to submit a New Drug Application in the US for Olanzapine LAI, a once monthly long acting injection for schizophrenia using its co polymer technology licensed to Teva, in the fourth quarter of 2025, following positive Phase 3 safety data (Product Related Announcement) UZEDY has received regulatory approval in South Korea and is showing strong commercial traction, with 2024 net sales of 117 million dollars and 95 million dollars already in the first half of 2025.分析記事 • Dec 01
MedinCell S.A.'s (EPA:MEDCL) 27% Cheaper Price Remains In Tune With Revenues
MedinCell S.A. ( EPA:MEDCL ) shares have retraced a considerable 27% in the last month, reversing a fair amount of...ナラティブの更新 • Nov 21
MEDCL: Index Inclusion Will Drive Increased Visibility And Market Confidence
Analysts have slightly reduced their fair value price target for MedinCell from $35.16 to $34.87, reflecting tempered expectations around revenue growth and profit margins. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which may enhance visibility among institutional investors and index-tracking funds.ナラティブの更新 • Nov 06
MEDCL: Profit Margins Are Expected To Improve Significantly With Recent FDA Approval
Analysts have raised their price target for MedinCell from $31.16 to $35.16. This change reflects increased confidence in the company’s future profitability and outlook, even though there is a slightly higher discount rate and moderated revenue growth projections.ナラティブの更新 • Oct 23
Analysts Lift MedinCell Price Target on Strong Revenue Outlook and Positive Regulatory Developments
Analysts have raised their price target for MedinCell from €26.90 to €31.16, citing improved revenue growth projections and favorable updates to future earnings expectations as key drivers for this upward revision. What's in the News FDA approves UZEDY, a once-monthly, long-acting risperidone injection, as monotherapy or adjunctive therapy for maintenance treatment of bipolar I disorder in adults.ナラティブの更新 • Oct 09
Global Expansion And Extended Patents Will Unlock Future Opportunities
Analysts have raised their price target for MedinCell from $24.47 to $26.90, citing stronger fair value projections and underlying optimism in the company’s financial outlook. What's in the News MedinCell plans to submit a New Drug Application (NDA) for Olanzapine LAI, a once-monthly long-acting treatment for schizophrenia, in the US during the fourth quarter of 2025 (Key Developments).ナラティブの更新 • Sep 25
Global Expansion And Extended Patents Will Unlock Future Opportunities
The upward revision in MedinCell's price target reflects a significant increase in consensus revenue growth forecasts coupled with a notable decline in the future P/E ratio, resulting in a new fair value estimate of €24.47. What's in the News UZEDY, a long-acting injectable risperidone for schizophrenia, received regulatory approval in South Korea and will be distributed by Teva Handok.分析記事 • Sep 25
Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge
The MedinCell S.A. ( EPA:MEDCL ) share price has done very well over the last month, posting an excellent gain of 30...新しいナラティブ • Sep 05
Global Expansion And Extended Patents Will Unlock Future Opportunities
Key Takeaways Expansion of UZEDY and BEPO®-based programs, along with strong partnerships, underpin growth and reduce reliance on a single product. Extended patent protection and real-world value evidence support sustained pricing power and margin strength amid growing demand globally.分析記事 • Jun 19
News Flash: Analysts Just Made A Substantial Upgrade To Their MedinCell S.A. (EPA:MEDCL) Forecasts
MedinCell S.A. ( EPA:MEDCL ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Dec 25
Industry Analysts Just Made An Incredible Upgrade To Their MedinCell S.A. (EPA:MEDCL) Revenue Forecasts
MedinCell S.A. ( EPA:MEDCL ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Jul 05
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
The latest analyst coverage could presage a bad day for MedinCell S.A. ( EPA:MEDCL ), with the analysts making...分析記事 • Apr 26
Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Despite an already strong run, MedinCell S.A. ( EPA:MEDCL ) shares have been powering on, with a gain of 30% in the...分析記事 • Jan 09
Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
The MedinCell S.A. ( EPA:MEDCL ) share price has done very well over the last month, posting an excellent gain of 26...分析記事 • Mar 02
The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
MedinCell S.A. ( EPA:MEDCL ) shareholders might be concerned after seeing the share price drop 17% in the last month...分析記事 • Jan 08
Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Every investor in MedinCell S.A. ( EPA:MEDCL ) should be aware of the most powerful shareholder groups. Large companies...株主還元
| MEDCL | FR Pharmaceuticals | FR 市場 | |
|---|---|---|---|
| 7D | 13.6% | 2.3% | 0.9% |
| 1Y | 75.3% | -2.9% | 4.6% |
業界別リターン: MEDCL過去 1 年間で-2.9 % の収益を上げたFrench Pharmaceuticals業界を上回りました。
リターン対市場: MEDCL過去 1 年間で4.6 % の収益を上げたFrench市場を上回りました。
価格変動
| MEDCL volatility | |
|---|---|
| MEDCL Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in FR Market | 10.9% |
| 10% least volatile stocks in FR Market | 2.6% |
安定した株価: MEDCLの株価は、 French市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: MEDCLの weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてFrenchの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2003 | 145 | Christophe Douat | www.medincell.com |
MedinCell S.A.は製薬会社で、フランスの様々な治療領域で長時間作用型注射剤を開発している。長時間作用型注射剤の技術であるBEPOに基づいたソリューションを開発し、成人の統合失調症治療薬UZEDY（mdc-IRM）を提供している。開発中の製品としては、セレコキシブの徐放性製剤で、術後の疼痛や炎症の軽減を適応症として第III相臨床試験中のmdc-CWM、統合失調症の治療を適応症として第III相臨床試験中の皮下注射剤mdc-TJKなどがある。前臨床試験中の製品候補としては、避妊用のmdc-WWM、マラリア用のmdc-STMがある。MedinCell S.A.は2003年に設立され、フランスのジャコウに本社を置いている。
MedinCell S.A. 基礎のまとめ
| MEDCL 基礎統計学 | |
|---|---|
| 時価総額 | €1.06b |
| 収益（TTM） | -€19.95m |
| 売上高(TTM) | €32.44m |
32.7x
P/Sレシオ-53.1x
PER（株価収益率MEDCL は割高か？
公正価値と評価分析を参照収益と収入
| MEDCL 損益計算書（TTM） | |
|---|---|
| 収益 | €32.44m |
| 売上原価 | €0 |
| 売上総利益 | €32.44m |
| その他の費用 | €52.39m |
| 収益 | -€19.95m |
直近の収益報告
Sep 30, 2025
次回決算日
Dec 08, 2026
| 一株当たり利益（EPS） | -0.56 |
| グロス・マージン | 100.00% |
| 純利益率 | -61.49% |
| 有利子負債／自己資本比率 | -232.2% |
MEDCL の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/03 19:45 |
| 終値 | 2026/07/03 00:00 |
| 収益 | 2025/09/30 |
| 年間収益 | 2025/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
MedinCell S.A. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12
| アナリスト | 機関 |
|---|---|
| David Seynnaeve | Degroof Petercam |
| Michael DiFiore | Evercore ISI |
| Raghuram Selvaraju | H.C. Wainwright & Co. |